On March 11, 2026, the FDA announced the launch of the FDA Adverse Event Monitoring System (AEMS), a unified platform designed to modernize and streamline the agency’s analysis of adverse event reports. This initiative marks a significant milestone in the FDA’s commitment to improving transparency and efficiency in postmarket surveillance of regulated products.
“The FDA’s previous adverse event reporting systems were outdated and fragmented and made important data difficult to access. These clunky systems also wasted millions of taxpayer dollars and created blind spots in our postmarket surveillance of products ranging from drugs and vaccines to cosmetics,” said FDA Commissioner Marty Makary, MD, MPH. “We’re fixing the problem through a major modernization initiative. Starting today, the FDA will have a single, intuitive adverse event platform that will better serve agency scientists, researchers, and the public.”
Key Features of AEMS
AEMS consolidates adverse event reports from multiple FDA-regulated product categories, including drugs, biologics, vaccines, cosmetics, and animal food, into a single dashboard. The platform will allow real-time processing and publication of adverse event data, replacing the agency’s former system of quarterly updates. By the end of May 2026, AEMS will cover all FDA-regulated products, enabling more efficient data analysis while protecting patient and consumer confidentiality.
The new platform addresses inefficiencies from the FDA’s previous patchwork of 7 databases, which collectively cost $37 million annually to operate and process approximately 6 million adverse event reports per year. With AEMS, the FDA expects to save approximately $120 million over 5 years and reduce Freedom of Information Act requests by making real-time data accessible to the public.
Enhancing Postmarket Surveillance
Adverse event reports, while limited in scope, are critical for identifying potential safety signals, such as patterns or clusters of adverse events that may indicate previously unknown risks. The streamlined and searchable AEMS platform will enhance the agency’s ability to detect and respond to such signals more effectively than before.
Technical Transformation and Future Plans
The FDA plans to migrate historical adverse event data into AEMS, decommission legacy systems, and introduce advanced application program interfaces and data analytics tools to further enhance usability. This effort, described by Chief AI Officer Jeremy Walsh as “the biggest technical transformation in agency history,” was completed under an aggressive timeline. The team executed with perfection, delivering a system that reflects the new, modern FDA, Walsh stated.
With AEMS, the FDA achieves a major leap forward in its mission to ensure the safety of regulated products, while demonstrating fiscal responsibility and a commitment to transparency.
Source
- FDA Launches New Adverse Event Look-Up Tool. www.fda.gov/news-events/press-announcements/fda-launches-new-adverse-event-look-tool